Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 51

1.

The Proliferative Activity of Mammary Epithelial Cells in Normal Tissue Predicts Breast Cancer Risk in Premenopausal Women.

Huh SJ, Oh H, Peterson MA, Almendro V, Hu R, Bowden M, Lis RL, Cotter MB, Loda M, Barry WT, Polyak K, Tamimi RM.

Cancer Res. 2016 Apr 1;76(7):1926-34. doi: 10.1158/0008-5472.CAN-15-1927. Epub 2016 Mar 3.

2.

Differential expression of neurogenes among breast cancer subtypes identifies high risk patients.

Fernández-Nogueira P, Bragado P, Almendro V, Ametller E, Rios J, Choudhury S, Mancino M, Gascón P.

Oncotarget. 2016 Feb 2;7(5):5313-26. doi: 10.18632/oncotarget.6543.

3.

In situ single-cell analysis identifies heterogeneity for PIK3CA mutation and HER2 amplification in HER2-positive breast cancer.

Janiszewska M, Liu L, Almendro V, Kuang Y, Paweletz C, Sakr RA, Weigelt B, Hanker AB, Chandarlapaty S, King TA, Reis-Filho JS, Arteaga CL, Park SY, Michor F, Polyak K.

Nat Genet. 2015 Oct;47(10):1212-9. doi: 10.1038/ng.3391. Epub 2015 Aug 24.

4.

The Transmodulation of HER2 and EGFR by Substance P in Breast Cancer Cells Requires c-Src and Metalloproteinase Activation.

Garcia-Recio S, Pastor-Arroyo EM, Marín-Aguilera M, Almendro V, Gascón P.

PLoS One. 2015 Jun 26;10(6):e0129661. doi: 10.1371/journal.pone.0129661. eCollection 2015.

5.

Comparison of methods for the isolation of human breast epithelial and myoepithelial cells.

Zubeldia-Plazaola A, Ametller E, Mancino M, Prats de Puig M, López-Plana A, Guzman F, Vinyals L, Pastor-Arroyo EM, Almendro V, Fuster G, Gascón P.

Front Cell Dev Biol. 2015 May 21;3:32. doi: 10.3389/fcell.2015.00032. eCollection 2015.

6.

The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer.

Muñoz M, González-Ortega A, Salinas-Martín MV, Carranza A, Garcia-Recio S, Almendro V, Coveñas R.

Int J Oncol. 2014 Oct;45(4):1658-72. doi: 10.3892/ijo.2014.2565. Epub 2014 Jul 28.

PMID:
25175857
7.

GoIFISH: a system for the quantification of single cell heterogeneity from IFISH images.

Trinh A, Rye IH, Almendro V, Helland A, Russnes HG, Markowetz F.

Genome Biol. 2014 Aug 26;15(8):442. doi: 10.1186/s13059-014-0442-y.

8.

Non-cell-autonomous driving of tumour growth supports sub-clonal heterogeneity.

Marusyk A, Tabassum DP, Altrock PM, Almendro V, Michor F, Polyak K.

Nature. 2014 Oct 2;514(7520):54-8. doi: 10.1038/nature13556. Epub 2014 Jul 30.

9.

JARID1B is a luminal lineage-driving oncogene in breast cancer.

Yamamoto S, Wu Z, Russnes HG, Takagi S, Peluffo G, Vaske C, Zhao X, Moen Vollan HK, Maruyama R, Ekram MB, Sun H, Kim JH, Carver K, Zucca M, Feng J, Almendro V, Bessarabova M, Rueda OM, Nikolsky Y, Caldas C, Liu XS, Polyak K.

Cancer Cell. 2014 Jun 16;25(6):762-77. doi: 10.1016/j.ccr.2014.04.024.

10.

Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity.

Almendro V, Cheng YK, Randles A, Itzkovitz S, Marusyk A, Ametller E, Gonzalez-Farre X, Muñoz M, Russnes HG, Helland A, Rye IH, Borresen-Dale AL, Maruyama R, van Oudenaarden A, Dowsett M, Jones RL, Reis-Filho J, Gascon P, Gönen M, Michor F, Polyak K.

Cell Rep. 2014 Feb 13;6(3):514-27. doi: 10.1016/j.celrep.2013.12.041. Epub 2014 Jan 23.

11.

Genetic and phenotypic diversity in breast tumor metastases.

Almendro V, Kim HJ, Cheng YK, Gönen M, Itzkovitz S, Argani P, van Oudenaarden A, Sukumar S, Michor F, Polyak K.

Cancer Res. 2014 Mar 1;74(5):1338-48. doi: 10.1158/0008-5472.CAN-13-2357-T. Epub 2014 Jan 21.

12.

Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.

Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, Engel P, Costamagna D, Fernandez PL, Gascón P, Almendro V.

Cancer Res. 2013 Nov 1;73(21):6424-34. doi: 10.1158/0008-5472.CAN-12-4573. Epub 2013 Sep 12.

13.

Molecular profiling of human mammary gland links breast cancer risk to a p27(+) cell population with progenitor characteristics.

Choudhury S, Almendro V, Merino VF, Wu Z, Maruyama R, Su Y, Martins FC, Fackler MJ, Bessarabova M, Kowalczyk A, Conway T, Beresford-Smith B, Macintyre G, Cheng YK, Lopez-Bujanda Z, Kaspi A, Hu R, Robens J, Nikolskaya T, Haakensen VD, Schnitt SJ, Argani P, Ethington G, Panos L, Grant M, Clark J, Herlihy W, Lin SJ, Chew G, Thompson EW, Greene-Colozzi A, Richardson AL, Rosson GD, Pike M, Garber JE, Nikolsky Y, Blum JL, Au A, Hwang ES, Tamimi RM, Michor F, Haviv I, Liu XS, Sukumar S, Polyak K.

Cell Stem Cell. 2013 Jul 3;13(1):117-30. doi: 10.1016/j.stem.2013.05.004. Epub 2013 Jun 13.

14.

Cellular heterogeneity and molecular evolution in cancer.

Almendro V, Marusyk A, Polyak K.

Annu Rev Pathol. 2013 Jan 24;8:277-302. doi: 10.1146/annurev-pathol-020712-163923. Epub 2012 Oct 22. Review.

PMID:
23092187
15.

Amplified loci on chromosomes 8 and 17 predict early relapse in ER-positive breast cancers.

Bilal E, Vassallo K, Toppmeyer D, Barnard N, Rye IH, Almendro V, Russnes H, Børresen-Dale AL, Levine AJ, Bhanot G, Ganesan S.

PLoS One. 2012;7(6):e38575. doi: 10.1371/journal.pone.0038575. Epub 2012 Jun 13.

16.

Evolutionary pathways in BRCA1-associated breast tumors.

Martins FC, De S, Almendro V, Gönen M, Park SY, Blum JL, Herlihy W, Ethington G, Schnitt SJ, Tung N, Garber JE, Fetten K, Michor F, Polyak K.

Cancer Discov. 2012 Jun;2(6):503-11. doi: 10.1158/2159-8290.CD-11-0325. Epub 2012 Apr 10.

17.

Intra-tumour heterogeneity: a looking glass for cancer?

Marusyk A, Almendro V, Polyak K.

Nat Rev Cancer. 2012 Apr 19;12(5):323-34. doi: 10.1038/nrc3261. Review.

PMID:
22513401
18.

Heterogeneity of breast cancer: etiology and clinical relevance.

Almendro V, Fuster G.

Clin Transl Oncol. 2011 Nov;13(11):767-73. doi: 10.1007/s12094-011-0731-9. Review.

PMID:
22082639
19.

Interleukin-15 affects differentiation and apoptosis in adipocytes: implications in obesity.

Fuster G, Almendro V, Fontes-Oliveira CC, Toledo M, Costelli P, Busquets S, López-Soriano FJ, Argilés JM.

Lipids. 2011 Nov;46(11):1033-42. doi: 10.1007/s11745-011-3594-5. Epub 2011 Sep 6.

PMID:
21894465
20.

Characterization of human pancreatic orthotopic tumor xenografts suitable for drug screening.

Pérez-Torras S, Vidal-Pla A, Miquel R, Almendro V, Fernández-Cruz L, Navarro S, Maurel J, Carbó N, Gascón P, Mazo A.

Cell Oncol (Dordr). 2011 Dec;34(6):511-21. doi: 10.1007/s13402-011-0049-1. Epub 2011 Jun 17.

21.

The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors.

Marotta LL, Almendro V, Marusyk A, Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ, Choudhury SA, Maruyama R, Wu Z, Gönen M, Mulvey LA, Bessarabova MO, Huh SJ, Silver SJ, Kim SY, Park SY, Lee HE, Anderson KS, Richardson AL, Nikolskaya T, Nikolsky Y, Liu XS, Root DE, Hahn WC, Frank DA, Polyak K.

J Clin Invest. 2011 Jul;121(7):2723-35. doi: 10.1172/JCI44745.

22.

The neuronal influence on tumor progression.

Mancino M, Ametller E, Gascón P, Almendro V.

Biochim Biophys Acta. 2011 Dec;1816(2):105-18. doi: 10.1016/j.bbcan.2011.04.005. Epub 2011 May 14. Review.

23.

Targeting of substance P induces cancer cell death and decreases the steady state of EGFR and Her2.

Mayordomo C, García-Recio S, Ametller E, Fernández-Nogueira P, Pastor-Arroyo EM, Vinyals L, Casas I, Gascón P, Almendro V.

J Cell Physiol. 2012 Apr;227(4):1358-66. doi: 10.1002/jcp.22848.

PMID:
21604273
24.

Differential regulation of MMP7 in colon cancer cells resistant and sensitive to oxaliplatin-induced cell death.

Ametller E, García-Recio S, Pastor-Arroyo EM, Callejo G, Carbó N, Gascón P, Almendro V.

Cancer Biol Ther. 2011 Jan 1;11(1):4-13. Epub 2011 Jan 1.

PMID:
20980803
25.

Tumor promoting effects of CD95 signaling in chemoresistant cells.

Ametller E, García-Recio S, Costamagna D, Mayordomo C, Fernández-Nogueira P, Carbó N, Pastor-Arroyo EM, Gascón P, Almendro V.

Mol Cancer. 2010 Jun 23;9:161. doi: 10.1186/1476-4598-9-161.

26.

8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC.

Ahmadiyeh N, Pomerantz MM, Grisanzio C, Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A, Macconaill L, Coetzee GA, Regan MM, Freedman ML.

Proc Natl Acad Sci U S A. 2010 May 25;107(21):9742-6. doi: 10.1073/pnas.0910668107. Epub 2010 May 7.

27.

Tyrosine kinase receptor transactivation associated to G protein-coupled receptors.

Almendro V, García-Recio S, Gascón P.

Curr Drug Targets. 2010 Sep;11(9):1169-80. Review.

PMID:
20450475
28.

Interleukin-15 increases calcineurin expression in 3T3-L1 cells: possible involvement on in vivo adipocyte differentiation.

Almendro V, Fuster G, Ametller E, Costelli P, Pilla F, Busquets S, Figueras M, Argilés JM, López-Soriano FJ.

Int J Mol Med. 2009 Oct;24(4):453-8.

PMID:
19724884
29.

The role of MMP7 and its cross-talk with the FAS/FASL system during the acquisition of chemoresistance to oxaliplatin.

Almendro V, Ametller E, García-Recio S, Collazo O, Casas I, Augé JM, Maurel J, Gascón P.

PLoS One. 2009;4(3):e4728. doi: 10.1371/journal.pone.0004728. Epub 2009 Mar 6.

30.

Effects of IL-15 on rat brown adipose tissue: uncoupling proteins and PPARs.

Almendro V, Fuster G, Busquets S, Ametller E, Figueras M, Argilés JM, López-Soriano FJ.

Obesity (Silver Spring). 2008 Feb;16(2):285-9. doi: 10.1038/oby.2007.47.

31.

Antiproteolytic effects of plasma from hibernating bears: a new approach for muscle wasting therapy?

Fuster G, Busquets S, Almendro V, López-Soriano FJ, Argilés JM.

Clin Nutr. 2007 Oct;26(5):658-61. Epub 2007 Sep 27.

PMID:
17904252
32.

Are peroxisome proliferator-activated receptors involved in skeletal muscle wasting during experimental cancer cachexia? Role of beta2-adrenergic agonists.

Fuster G, Busquets S, Ametller E, Olivan M, Almendro V, de Oliveira CC, Figueras M, López-Soriano FJ, Argilés JM.

Cancer Res. 2007 Jul 1;67(13):6512-9.

33.

Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients.

Maurel J, Nadal C, Garcia-Albeniz X, Gallego R, Carcereny E, Almendro V, Mármol M, Gallardo E, Maria Augé J, Longarón R, Martínez-Fernandez A, Molina R, Castells A, Gascón P.

Int J Cancer. 2007 Sep 1;121(5):1066-71.

34.

Targets in clinical oncology: the metabolic environment of the patient.

Argilés JM, Busquets S, Moore-Carrasco R, Figueras M, Almendro V, López-Soriano FJ.

Front Biosci. 2007 May 1;12:3024-51. Review.

PMID:
17485280
35.

Modulations of the calcineurin/NF-AT pathway in skeletal muscle atrophy.

Costelli P, Almendro V, Figueras MT, Reffo P, Penna F, Aragno M, Mastrocola R, Boccuzzi G, Busquets S, Bonelli G, Lopez Soriano FJ, Argilés JM, Baccino FM.

Biochim Biophys Acta. 2007 Jul;1770(7):1028-36. Epub 2007 Mar 16.

PMID:
17442496
36.

The AP-1/NF-kappaB double inhibitor SP100030 can revert muscle wasting during experimental cancer cachexia.

Moore-Carrasco R, Busquets S, Almendro V, Palanki M, López-Soriano FJ, Argilés JM.

Int J Oncol. 2007 May;30(5):1239-45.

PMID:
17390027
37.

Interleukin-15 increases glucose uptake in skeletal muscle. An antidiabetogenic effect of the cytokine.

Busquets S, Figueras M, Almendro V, López-Soriano FJ, Argilés JM.

Biochim Biophys Acta. 2006 Nov;1760(11):1613-7. Epub 2006 Sep 12.

PMID:
17056184
38.

Inhibitors of angiogenesis.

Almendro V, Gascón P.

Clin Transl Oncol. 2006 Jul;8(7):475-81. Review.

PMID:
16870537
39.

Effects of interleukin-15 on lipid oxidation: disposal of an oral [(14)C]-triolein load.

Almendro V, Busquets S, Ametller E, Carbó N, Figueras M, Fuster G, Argilés JM, López-Soriano FJ.

Biochim Biophys Acta. 2006 Jan;1761(1):37-42. Epub 2006 Jan 18.

PMID:
16458591
40.

Interleukin-15 decreases proteolysis in skeletal muscle: a direct effect.

Busquets S, Figueras MT, Meijsing S, Carbó N, Quinn LS, Almendro V, Argilés JM, López-Soriano FJ.

Int J Mol Med. 2005 Sep;16(3):471-6.

PMID:
16077957
41.

Cancer cachexia results in an increase in TNF-alpha receptor gene expression in both skeletal muscle and adipose tissue.

Figueras M, Busquets S, Carbó N, Almendro V, Argilés JM, López-Soriano FJ.

Int J Oncol. 2005 Sep;27(3):855-60.

PMID:
16077938
42.

Interleukin-15 decreases lipid intestinal absorption.

Almendro V, Carbó N, Busquets S, López-Soriano J, Figueras M, Ametller E, Argilés JM, López-Soriano FJ.

Int J Mol Med. 2005 Jun;15(6):963-7.

PMID:
15870900
43.
44.

Cross-talk between skeletal muscle and adipose tissue: a link with obesity?

Argilés JM, López-Soriano J, Almendro V, Busquets S, López-Soriano FJ.

Med Res Rev. 2005 Jan;25(1):49-65. Review.

PMID:
15389734
45.

Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting.

Busquets S, Figueras MT, Fuster G, Almendro V, Moore-Carrasco R, Ametller E, Argilés JM, López-Soriano FJ.

Cancer Res. 2004 Sep 15;64(18):6725-31.

46.

Interleukin-15 is able to suppress the increased DNA fragmentation associated with muscle wasting in tumour-bearing rats.

Figueras M, Busquets S, Carbó N, Barreiro E, Almendro V, Argilés JM, López-Soriano FJ.

FEBS Lett. 2004 Jul 2;569(1-3):201-6.

47.

Rat liver lipogenesis is modulated by interleukin-15.

López-Soriano J, Carbó N, Almendro V, Figueras M, Ribas V, Busquets S, López-Soriano FJ, Argilés JM.

Int J Mol Med. 2004 Jun;13(6):817-9.

PMID:
15138618
48.

The pharmacological treatment of cachexia.

Argilés JM, Almendro V, Busquets S, López-Soriano FJ.

Curr Drug Targets. 2004 Apr;5(3):265-77. Review.

PMID:
15058312
49.

Sepsis induces DNA fragmentation in rat skeletal muscle.

Almendro V, Carbó N, Busquets S, Figueras M, Tessitore L, López-Soriano FJ, Argilés JM.

Eur Cytokine Netw. 2003 Oct-Dec;14(4):256-9.

50.

Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?

Busquets S, Carbó N, Almendro V, Figueras M, López-Soriano FJ, Argilés JM.

FEBS Lett. 2001 Sep 14;505(2):255-8.

Supplemental Content

Loading ...
Support Center